Jerome Thurman
Endocrinology, Diabetes & Metabolism · Saint Charles, MONPI 1194793943
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $276,247 of the $312,012 with a category attached, or 88.5%. 21 manufacturers reported payments, led by Novo Nordisk at 37.8% of the total. Reporting peaked in 2019 at $78,520 and has fallen 74.0% since, to $20,378 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 661 payments — averaging $472.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$118K
- AstraZeneca$63K
- Sanofi-aventis U.S. LLC$59K
- Bayer$37K
- Dexcom, Inc.$18K
- Medtronic$8K
- plus $8K from 15 others
What the payments were for
- Consulting fees$5,3782%
- Speaking & faculty fees$276,24789%
- Travel & lodging$13,3834%
- Food & beverage$16,8525%
- Education$920%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $118,003 |
| AstraZeneca | 117 | $62,905 |
| Sanofi-aventis U.S. LLC | 71 | $59,002 |
| Bayer | 26 | $37,193 |
| Dexcom, Inc. | 74 | $18,394 |
| Medtronic(2 entities) | 94 | $8,330 |
| Boehringer Ingelheim | 4 | $3,750 |
| Abbott | 60 | $2,060 |
| Sequel Med Tech, LLC | 29 | $658 |
| Lilly USA, LLC | 5 | $547 |
| Insulet Corporation | 17 | $381 |
| Mannkind Corporation | 3 | $279 |
| Ascendis Pharma Endocrinology Inc | 4 | $186 |
| Amgen | 1 | $122 |
| Antares Pharma, Inc. | 1 | $72 |
| Pfizer | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| AbbVie | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$60,956
- Ozempic$54,488
- RYBELSUS$52,092
- TOUJEO$38,480
- Kerendia$33,562
- SOLIQUA 100/33$31,807
- DEXCOM G7 GSS (161)$14,759
- Tresiba$6,366
- JARDIANCE$4,238
- DEXCOM G6 TRANSMITTER$2,850
- MINIMED 770G$1,650
- Minimed 630G$1,513
- Minimed 670G System$1,366
- FreeStyle Libre 2$419
- TZIELD$353
- MINIMED 780G$289
- FREESTYLE LIBRE 3$255
- DEXCOM CGM$224
- AFREZZA$153
- TWIIST$149
How this compares
$312,012 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 671 | $997,270 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 364 | $415,287 |
| FarxigaDapagliflozin Propanediol | 392 | $369,187 |
| Tresiba Flextouch U-200Insulin Degludec | 146 | $288,804 |
| JardianceEmpagliflozin | 172 | $216,518 |
| TrulicityDulaglutide | 110 | $178,574 |
| ProliaDenosumab | 61 | $105,095 |
| SomavertPegvisomant | 12 | $98,348 |
| Tresiba Flextouch U-100Insulin Degludec | 129 | $90,346 |
| MounjaroTirzepatide | 62 | $82,470 |
| Bydureon BciseExenatide Microspheres | 43 | $61,870 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $60,256 |
| TymlosAbaloparatide | 15 | $55,656 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $47,079 |
| JanuviaSitagliptin Phosphate | 27 | $44,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $118,003 | $1,122,925774 claims |
| AstraZenecaFarxiga | $62,905 | $369,187392 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $547 | $273,079216 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $3,750 | $247,004202 claims |
| AmgenProlia | $122 | $105,09561 claims |
| PfizerSomavert | $31 | $98,34812 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $59,002 | $41,16041 claims |
| AbbVieSynthroid | $17 | $22,390237 claims |
| BayerKerendia | $37,193 | $18,92326 claims |
| Antares Pharma, Inc.Xyosted | $72 | $15,67016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Charles
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
- Adam MaghrabiBlue Springs$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.